Trans-BBB delivery methods that use targeting vectors to coopt the vesicle trafficking machinery of BBB endothelial cells have been developed, but these are often hampered by limited flux through the BBB.
These studies were conducted using tumour xenografts, in which a hypoxia-responsive gene, such as the 5HREp-luciferase or the 5HREp GFP gene, had been previously set, but never using vectors responsible for the trans-gene delivery.
However, until now there are no microneedle-based (trans)dermal drug delivery systems on the market.
These microneedles have been used for different approaches of microneedle-based (trans)dermal drug delivery.
Besides, the four microneedle-based (trans)dermal drug delivery approaches are discussed: "poke and flow", "poke and patch", "poke and release", and "coat and poke".
Finally, we give our view on research and development that is needed to render microneedle-based (trans)dermal drug delivery technologies clinically useful in the near future.
These synthetic mucin networks can potentially serve as a modular in vitro model in studying trans-mucosal drug delivery.
Here, we tested whether the non-viral Sleeping Beauty (SB) transposon system could mediate stable delivery of trans-splicing molecules designed to correct the genetic defect responsible for severe combined immune deficiency (SCID).
The experiments and numerical model outlined in this study could also be adjusted to more general formulations, which enhances the utility of the numerical model as a design tool for the development of drug-loaded matrices for trans-membrane and transdermal delivery.
Foods direct from nature, and minimally processed foods were never delivery vehicles for trans fat in the first place.
Here, we show that the 4R/3R tau isoform ratio can be increased in neurons from htau mice in culture and in vivo by RNA trans-splicing after lentivirus-mediated delivery of tau-targeted PTMs.
